RxDoctor Payments Data

Eric Roccario, MD

Interventional Cardiology · Albany, NYNPI 1538167697

Payments from drug & device makers

$27,315in general payments, 2019–2025

Across 286 payments — averaging $95.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardiovascular Systems Inc.$15K
  • Edwards Lifesciences$9K
  • Abbott$861
  • Abiomed$636
  • Boston Scientific$330
  • Artivion, Inc.$237
  • plus $1K from 13 others

What the payments were for

  • Consulting fees$3,25028%
  • Travel & lodging$2,69723%
  • Food & beverage$5,60749%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,315 in reported general payments places this provider in the 65th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$180,911
Medicare patients
753
Services billed
1,653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban316$430,971
Repatha SureclickEvolocumab164$158,356
BrilintaTicagrelor146$126,611
JardianceEmpagliflozin87$101,078
Praluent PenAlirocumab82$82,952
EntrestoSacubitril/Valsartan59$75,161
FarxigaDapagliflozin Propanediol42$45,645
Ranolazine ErRanolazine342$42,126
NexlizetBempedoic Acid/Ezetimibe27$28,371
XareltoRivaroxaban16$25,210
VascepaIcosapent Ethyl15$14,543
Ezetimibe468$13,281
Atorvastatin Calcium1,032$12,376
NexletolBempedoic Acid21$11,337
Metoprolol Succinate692$10,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$111$430,971316 claims
Boehringer IngelheimJardiance$44$101,07887 claims
NovartisEntresto$173$75,16159 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →